肺癌疫苗:開發平台，策略，臨床

肺癌疫苗:開發平台，策略，臨床 是由出版商BioPharm Reports (Technology and Markets Ltd)在2011年10月所出版的。 這份英文市場調查報告書包含135 Pages 價格從美金1520起跳。

簡介

肺癌是全球最常見的癌症，2008年有160萬件新的病例，導致140萬人死亡(癌症的整體死亡人數差不多為20％)。5年存活率與其他的癌症相比稍微低一點(15∼20％)。美國的肺癌治療費用(2006年)在全部的癌症中最貴。

本報告提供肺癌疫苗市場相關整體分析，肺癌治療主要適用的研究開發與臨床開發趨勢等彙整資料，為您概述為以下內容。

摘要整理

第1章 背景

• 肺癌
  • 統計
  • 診斷
  • 肺癌的分期
  • 肺癌治療
  • 存活率
  • 肺癌成本
  • 新的開發
  • 本報告
  • 參考

第2章 已通過核准及後期階段的疫苗

• 簡介
• 概要
• 已通過核准疫苗
• 第三階段疫苗
• 第2/3階段疫苗
• 參考

第3章 早期階段疫苗

• 簡介
• 概要
• 第二階段疫苗
• 第1/2階段疫苗
• 第一階段疫苗
• 前臨床階段疫苗
• 參考

第4章 其他的候選治療藥物

• 簡介
• 概要
• 免疫活化劑:第二階段
• 抗體共軛:第1/2階段
• 雙特異性抗體:第一階段
• 抗體共軛:第一階段
• 免疫刺激劑:第一階段
• 抗體共軛:第一階段
• 參考

第5章 考察

• 背景
• 開發平台
• 疫苗
• 其他的候選治療藥物
• 企業
• 治療標靶
• 治療方法
• 症狀
• 市場展望
• 參考

圖表

目錄

Abstract

This report provides a comprehensive review of 42 candidate vaccines that are being evaluated for the treatment of lung cancer, covering pipeline, disease-targeting strategies and clinical findings. These vaccines are directed at 24 antigens or antigen combinations.

Globally, lung cancer is the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers. In the US, studies have shown that lung cancer-care costs (in 2006) were the third highest of all cancers, while indirect costs (2005) were higher than for any other cancer.

Patient needs and the high burden of lung cancer drive the development of new therapies. While improvements have been seen in diagnosis and treatments (surgery, radiotherapy, chemotherapy and targeted drugs), new therapies that build on the capabilities of existing approaches, are urgently required. Today, developments continue to be made in drug treatments for lung cancer; in chemotherapy, new drug combinations and targeted molecules. In particular, advances are being seen in the field of immunotherapy; in the development of new therapeutic antibodies and therapeutic vaccines.

This report provides a comprehensive review of lung cancer vaccines and reviews R&D and clinical developments in the treatment of lung cancer as the primary indication, as well as studies that are evaluating lung cancer alongside other cancers.

Today, more than 40 candidate lung cancer vaccines are in development or being evaluated for the treatment of lung cancer, most of which are already in clinical trials. This field is also showing substantial innovation and 24 different antigen/multiple antigen targeting strategies are being investigated. For the purpose of this report, multiple antigen targeting approaches have been treated as single strategies. This report gives an overview of the status and clinical findings of these candidate vaccines, and gives developmental and market-related perspectives in this rapidly developing field.

• Late-stage (Phases 2/3, 3 and Approved, n = 5) pipeline vaccines and companies
• Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 37) pipeline vaccines and companies
• Other (mainly antibody related, n=6) candidate therapies in the development pipeline for targeting lung cancer, Phase 1, 1/2 and 2
• Antigens/antigen combinations being targeted by vaccines from preclinical through to Phase 3 and Approved
• Descriptions of clinical trials (patients and numbers, conditions, treatments, regimens, Phase 1-3) of therapeutic vaccines being evaluated for the treatment of lung cancer
• Summaries of clinical status and clinical findings (safety, adverse events and multiple event-related clinical responses) reported following clinical trials (Phase 1-3) of vaccines being evaluated for the treatment of lung cancer
• Commercial partnerships and collaborations on pipeline therapeutic vaccines
• Drug combination strategies in the evaluation of therapeutic vaccines for the targeting of lung cancer
• A comprehensive listing of salient details of clinical trials of therapeutic vaccines being evaluated for the treatment of lung cancer
• Technical and market insights and perspectives in the development and clinical evaluation of therapeutic vaccines for the treatment of lung cancer
• Competitive and market-related information

Table of Contents

Executive Summary

Chapter 1 - Background

• Summary

• 1. Lung Cancer
  • 1.1. Statistics
  • 1.2. Diagnosis
  • 1.3. Lung Cancer Staging
  • 1.4. Treatment of Lung Cancer
  • 1.5. Survival Rates
  • 1.6. Cost of Lung Cancer
  • 1.7. New Developments
  • 1.8. This Report

• References

Chapter 2 - Approved and Late-Stage Vaccines

• Summary
  • 2.1. Introduction
  • 2.2. Overview
  • 2.3. (One vaccine, Approved)
  • 2.4. - 2.6 (Three vaccines, Phase 3)
  • 2.7. (One vaccine, Phase 2/3)

• References

Chapter 3 - Early-Stage Vaccines

• Summary
  • 3.1. Introduction
  • 3.2. Overview
  • 3.3. - 3.12 (Ten vaccines, Phase 2)
  • 3.13. - 3.22 (Ten vaccines, Phase 1/2)
  • 3.23. - 3.37 (Fifteen vaccines, Phase 1)
  • 3.38. - 3.39 (Two Vaccines, Preclinical)

• References

Chapter 4 - Other Candidate Therapies

• Summary
  • 4.1. Introduction
  • 4.2. Overview
  • 4.3. (One Immune Activator, Phase 2)
  • 4.4. (One Antibody Conjugate, Phase 1/2)
  • 4.5. (One Bispecific Antibody, Phase 1)
  • 4.6. (One Antibody Conjugate, Phase 1)
  • 4.7. (One Immune Stimulant, Phase 1)
  • 4.8. (One Antibody Conjugate, Phase 1)

• References

Chapter 5 - Discussion

• Summary
  • 5.1. Background
  • 5.2. Pipeline
  • 5.3. Vaccines
  • 5.4. Other Candidate Therapies
  • 5.5. Companies
  • 5.6. Therapeutic Targets
  • 5.7. Therapeutic Approaches
  • 5.8. Conditions
  • 5.9. Market Perspectives

• References

Tables

• Global incidence and mortality from lung cancer, 2008
• NSCLC survival rates, according to cancer stage
• 1.3a. Five-year relative cancer survival rates in the USA for white males
• 1.3b. Five-year relative cancer survival rates in the USA for white females
• US national expenditure on different cancers (2006)
• US lost productivity due to different cancer types in the US, 2005
• 2.1. Approved/late-stage vaccines for the treatment of lung cancer
• 3.1. Early-stage vaccines being developed or evaluated for the treatment of lung cancer or lung cancer/other cancers
• 4.1. Other (largely antibody-related) therapies being developed or evaluated for the treatment of lung cancer or lung cancer/other cancers
• 5.1. Approved/late-stage candidate vaccines being developed for the treatment of lung cancer
• 5.2. Early-stage candidate vaccines being developed or evaluated for lung cancer or for lung/other cancers
• Other (primarily antibody-related) therapies in development or being evaluated for lung cancer or for lung cancer/other cancers
• Approved/candidate vaccines for the treatment of lung cancer or for lung cancer/other cancers
• Other candidate therapies (primarily antibody-related) for the treatment of lung cancer or for lung cancer/other cancers
• NSCLC survival rates, according to cancer stage

Figures

• 3.1. Early-staged pipeline vaccines for the treatment of lung cancer or lung cancer/other cancers
• 5.1. Early-stage pipeline vaccines in development or being evaluated for lung cancer or for lung/other cancers
• 5.2. Other (primarily antibody-related) early-stage candidate therapies in development or being evaluated for lung cancer or for lung cancer/other cancers
• 5.3. Organisations developing or evaluating lung cancer therapeutic vaccines
• 5.4. Clinical trials of vaccines for the treatment of lung cancer or lung cancer/other cancers, involving single or combination agents

相關商品

疫苗相關市場調查報告書

大腸癌、癌症疫苗、蛋白質激酶抑制劑分析
Triple Analysis: Colorectal Cancer, Cancer Vaccines and Protein Kinase Inhibitors
價格 : US $ 5175
出版日期 : 2012年05月

白血病、癌症疫苗、蛋白質激酶抑制劑：藥劑開發策略分析
Triple Analysis: Leukemia, Cancer Vaccines and Protein Kinase Inhibitors
價格 : US $ 5175
出版日期 : 2012年05月

淋巴癌、癌症疫苗、蛋白質激酶抑制劑：藥劑開發策略分析
Triple Analysis: Lymphoma, Cancer Vaccines and Protein Kinase Inhibitors
價格 : US $ 5175
出版日期 : 2012年05月

BioPharm Reports (Technology and Markets Ltd)發行的製藥相關市場調查報告書

全球抗生素抗性市場(2012年):抗生素開發平台及抗生素抗性的對抗策略

Antibiotic Resistance 2012: The Antibiotic Development Pipeline and Strategies to Combat Antibiotic Resistance

價格 : US $ 2300

出版日期 : 2012年01月

肺癌疫苗和治療用抗體：生產線、策略、臨床

Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical

價格 : US $ 2384

出版日期 : 2011年10月

肺癌治療用抗體:開發平台，策略，臨床

Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical

價格 : US $ 1200

出版日期 : 2011年10月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!